SAM #HT9402-26-Q-9301

DHA Solicitation for ADHD Stimulants and BRAF-MEK Inhibitor Pharmaceuticals for Military Health System

The Defense Health Agency (DHA) is soliciting quotations for pharmaceutical agents to be evaluated for inclusion in the Military Health System (MHS) Uniform Formulary. - Government Buyer: - Defense Health Agency (DHA), Department of Defense - Managed Care Contract Directorate, Aurora, CO - Products/Services Requested: - Pharmaceutical agents in two categories: - ADHD Agents – Stimulants: - AZSTARYS - COTEMPLA XR-ODT - DYANAVEL XR - JORNAY PM - MYDAYIS - QUILLICHEW ER - QUILLIVANT XR - XELSTRYM - Oncological Agents – BRAF-MEK Inhibitors: - BRAFTOVI - COTELLIC - MEKINIST - MEKTOVI - TAFINLAR - ZELBORAF - Specific part numbers and quantities are referenced in attachments (not provided here) - OEMs and Vendors Mentioned: - Corium (AZSTARYS) - Neos Therapeutics (COTEMPLA XR-ODT, DYANAVEL XR) - Ironshore Pharmaceuticals (JORNAY PM) - Shire (MYDAYIS, QUILLICHEW ER, QUILLIVANT XR) - Noven Therapeutics (XELSTRYM) - Array BioPharma/Pfizer (BRAFTOVI, MEKTOVI) - Genentech (COTELLIC, ZELBORAF) - Novartis (TAFINLAR, MEKINIST) - Notable Requirements: - Products will be considered for inclusion in the Uniform Formulary and may result in Blanket Purchase Agreements (UF BPA) or Additional Discount Program Agreements (UF ADP) - No unique technical requirements specified beyond formulary selection and cost-sharing classification - Place of Performance: - San Antonio, TX, USA - Contracting Office: - Aurora, CO, USA

Description

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: The following August 2026 drug classes/subclasses will be reviewed:

a. ADHD Agents – Stimulants

AZSTARYS COTEMPLA XR-ODT DYANAVEL XR JORNAY PM MYDAYIS QUILLICHEW ER QUILLIVANT XR XELSTRYM

b. Oncological Agents - BRAF-MEK Inhibitors

BRAFTOVI COTELLIC MEKINIST MEKTOVI TAFINLAR ZELBORAF

The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9301. Pre-quotation teleconference is on May 13, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Additional Links:https://health.mil/PandT

View original listing